FindTrial
Sign In

Trattamento dell’epatocarcinoma (HCC) mediante chemioembolizzazione (TACE) selettiva tradizionale versus TACE selettiva con microsfere caricate con Doxorubicina: studio monocentrico, randomizzato, in aperto, controllato. - RAD01

Trattamento dell’epatocarcinoma (HCC) mediante chemioembolizzazione (TACE) selettiva tradizionale versus TACE selettiva con microsfere caricate con Doxorubicina: studio monocentrico, randomizzato, in aperto, controllato. - RAD01

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-003034-15-IT
Enrollment
214
Registered
2007-07-06
Start date
2006-07-11
Completion date
Unknown
Last updated
2022-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocarcinoma (HCC) MedDRA version: 6.1 Level: PT Classification code 10019695

Interventions

Trade Name: CAELYX*INFUS 1FL 2MG/ML 25ML Pharmaceutical Form: Solution for injection INN or Proposed INN: Doxorubicin CAS Number: 25316-40-9 Concentration unit: mg milligram(s) Concentration type: equ

Sponsors

AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The English version will follow Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: The English version will follow

Design outcomes

Primary

MeasureTime frame
Main Objective: The English version will follow;Secondary Objective: The English version will follow;Primary end point(s): The English version will follow—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026